It is made available under a CC-BY-NC-ND 4.0 International license .

1 Novel multiplex tools in an epidemic panel improve prediction of RSV infection dynamics

2 and disease burden – a RESPINOW analysis

- 3
- 4 Manuela Harries¹ *, Carolina J. Klett-Tammen¹ *, Isti Rodiah¹, Alex Dulovic², Veronika K
- 5 Jaeger³, Jessica Krepel¹, Sebastian Contreras⁴, Katrin Maak¹, Patrick Marsall², Annette
- 6 Möller¹, Jana-Kristin Heise¹, Stefanie Castell¹, RESPINOW study group, Nicole Schneiderhan-
- 7 Marra², André Karch^{3\$}, Berit Lange^{1, 5\$}
- 8 *shared first authorship
- 9 \$ shared last authorship

10 **Corresponding author:**

- 11 Manuela Harries
- 12 Helmholtz Centre for Infection Research
- 13 Department of Epidemiology
- 14 Inhoffenstraße 7
- 15 38124 Braunschweig
- 16 Germany
- 17 E-Mail: <u>Manuela.Harries@helmholtz.de</u>
- 18 Phone: +49(0)531-6181-3126
- 19
- 20 ¹ Helmholtz Centre for Infection Research, Department of Epidemiology, Braunschweig,
- 21 Germany
- ² NMI Natural and Medical Sciences Institute at the University of Tübingen (NMI), Reutlingen,
- 23 Germany
- ³ Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
- ⁴ Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany
- ⁵ German Centre for Infection Research (DZIF), TI BBD, Braunschweig, Germany

27

28 Abstract

- 29 Respiratory Syncytial Virus (RSV) is one of the leading causes of morbidity and mortality
- 30 among infants and adult risk groups worldwide. Substantial case-underdetection and gaps in
- 31 the understanding of reinfection dynamics of RSV limit reliable projection estimates.
- 32 Here, we use a novel RSV multiplex serological assay in a population-based panel to estimate
- 33 season and age-specific probability of reinfection and combine it with sentinel and
- 34 notification data to parameterize a mathematical model tailored to project RSV dynamics in
- 35 Germany from 2020 to 2023.

It is made available under a CC-BY-NC-ND 4.0 International license .

Our reinfection estimates, based on a 20% post-F and a 45% N antibody increase in the assay over consecutive periods, were 5.7% (95%CI: 4.7-6.9) from 2020 to 2022 and 12.7% (95%CI: 10.5-15.2) from 2022 to 2023 in adults. In 2021, 30-39 year olds had a higher risk of reinfection, whereas in 2022, all but the 30-39 age group had an increased risk of reinfection. This suggests age-differential infection acquisition in the two seasons, e.g. due to still stronger public health measures in place in 2021 than in 2022.

42 Model-based projections that include the population-based reinfection estimations 43 predicted the onset and peak for the 23/24 RSV season better than those only based on 44 surveillance estimates.

Rapid, age-specific reinfection assessments and models incorporating this data will be critical
for understanding and predicting RSV dynamics, especially with changing post-pandemic
patterns and new prevention strategies e.g. monoclonal antibody.

Helmholtz Association, EU Horizon 2020 research and innovation program, Federal Ministry
of Education and Research, and German Research supported this work.

50 Introduction

Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in 51 infants and adults^{1,2}. RSV causes only partial immunity, so that reinfections are an important 52 part of transmission dynamics^{3,4}. Typically, the primary infection in young children causes 53 54 severe disease, leading to an estimated 245,244 annual hospital cases in Europe, with most of them being infants (under 1 years)⁵. Reinfections are typically not as severe. However, 55 among the elderly (60+), they led to approximately 470,000 hospitalizations and 33,000 56 deaths in high-income countries in 2019¹. Despite these high numbers, RSV has only recently 57 been categorized as a notifiable disease in the majority of EU/EEA countries⁶, e.g. since July 58 2023 in Germany⁷. While this will result in an increase in publicly accessible data, without 59 targeted efforts to correct systematic biases like health care seeking behavior, usability of 60 61 this data for dynamic modelling remains limited due to age- and season differential 62 underdetection⁸.

63 Changes in post-pandemic RSV patterns and the roll-out of new preventive strategies are
64 expected to substantially affect RSV dynamics in the upcoming years.

Prior the COVID-19 pandemic, RSV infections peaked in early January in many European
countries⁹. However, from 2020 to 2022, the dynamics of RSV infections and hospitalizations
shifted. This change was partly influenced by the implementation of non-pharmaceutical
interventions (NPIs), which impacted all respiratory pathogens¹⁰⁻¹³.

It is made available under a CC-BY-NC-ND 4.0 International license .

As novel prevention strategies two vaccines have been approved in Europe for the elderly (GSK, RSVPreF3) and pregnant women (Pfizer, PF-06928316)^{14,15}; moreover, two monoclonal antibodies are licensed for (preterm) newborns and infants (under 8 months). Real-world evidence from the population-wide implementation of these prevention strategies shows high potential for reducing disease burden¹⁶. As a consequence, several European countries have defined implementation strategies¹⁷⁻¹⁹.

Current understanding of RSV transmission dynamics relies partly on seroprevalence 75 studies²⁰, which are often non-continuous and lack real-time and season-specific estimates. 76 This makes them insufficient for reliable age-group projections. More importantly, 77 78 transmission dynamics after early childhood and the effects of prior infections on secondary infections are mostly unknown²¹. In this study, we used data from an RSV multiplex 79 80 serological assay in an infectious disease focussed population-based cohort (MuSPAD) to 81 estimate adult age and season-specific reinfection probability. We combined this information with sentinel and RSV notification datasets to improve predictions from a 82 83 mathematical model for RSV trends in Germany.

84 Methods

85 Study design

86 We re-invited MuSPAD (Multilocal and Serial Prevalence Study of Antibodies against Infectious Diseases in Germany²²) participants from three (June-July 2022) and four (April-87 June 2023) regions²³ (fig S1). Using a multiplex-based serological assay, we measured RSV 88 IgG antibodies titres changes to RSV post-F protein from 2020 to 2023. The antigen-derived 89 90 9-plex immunoassay measures antibody titres towards post-F, Nucleoprotein (N), G proteins and subtype A or subtype B G antibodies that allowed classification as a prior infection with 91 either subtype A or subtype B²⁴. We evaluated different cut offs for reinfection definition 92 93 (post-F $\Delta 20$ -40%). We measured antibody titres at three intervals: baseline 2020/21, June-94 July 2022 and April-June 2023 representing RSV seasons 2021/2022 and 2022/2023 (figure 95 1).

It is made available under a CC-BY-NC-ND 4.0 International license .



96

Figure 1: Weekly extrapolated numbers of confirmed RSV cases (notifications of RSV was limited to the state of Saxony) in Germany (light grey area RSV season CW40-20) from 2016-2023 including sampling periods of the MuSPAD participants (1stsampling 2020/21 n= 32,561(dark grey shaded area), 2nd sampling 2022 n=1,754 (red shaded area), 3rd sampling 2023 n=2,832 (yellow shaded area). Enrolment of 836 participants with three sampling points.

We collected data on age, sex, household composition, sociodemographic, and health
 factors. Prior SARS-CoV-2 infection was detected by IgG antibodies against the Nucleocapsid
 (NC) antigen.

105 We provided a description of the study population and analysed Δ titre changes of two 106 proteins (cut off value of 20% post-F and additionally 45% N-protein for quality assurance) to 107 identify RSV reinfections in age groups (18-29, 30-39, 40-49, 50-59, 60-69, 70-79 and 80+ 108 years). We assume Δ 2020-2022 represents the 2021/22 RSV season and Δ 2022-2023 the 109 2022/23 RSV season, since few cases were reported between 2020 and 2021.

We used logistic regression to explore how age, children under 14 in the household, and SARS-CoV-2 serology affect reinfection risk each season. We adjusted for household size, SARS-CoV-2 vaccination status, age, chronic lung disease, contacts, and children under 14 living in the household, study region, and sex/gender. Additional variables were based on peer-reviewed Directed Acyclic Graphs (Supplement DAG). Adjusted relative risks (RR) and their 95% confidence intervals (CIs) were computed from the information provided in the respective logistic model fits (Supplement).

It is made available under a CC-BY-NC-ND 4.0 International license .

117 We determined the probability of reinfection for each age group independently for 2021-

118 2022 and 2022-2023. This probability is calculated using the two fitted logistic regression

119 models. The statistical analyses were performed using R Version 4.0.2 and STATA/IC 14.2.

120 Additional data sources

We used publicly accessible data. Details are in supplement, but in short for RSV notifications (2017-2023) we used notification data from Saxony from the public database on reportable diseases (SurvStat@RKI). We extrapolated Saxony's age-specific data using national population statistics to estimate figures for Germany. Country-wide notification of RSV cases was only fully implemented in Germany in 2023.

We extracted weekly data on acute respiratory infections (ARI) and influenza-like illness (ILI) from 2016 to 2023 using two sources: Arbeitsgemeinschaft Influenza (AGI) and GrippeWeb. AGI is a sentinel surveillance system testing for various respiratory infections, and GrippeWeb is a citizen science platform. GrippeWeb users report regularly online ARI or ILI symptoms. We applied the positive RSV proportion from the AGI to the GrippeWeb users to estimate RSV infections for each age group, and projected this for Germany. This dataset is used in the estimation of age- and year specific underdetection factors.

For hospitalizations we used the RSV proportion of the hospital sentinel ICOSARI (ICD-10 code-based hospital surveillance of severe acute respiratory infections (SARI)) surveillance from the AGI. We extrapolated these to nationwide estimates to generate the RSV hospitalization rates for Germany.

137 Age-specific SEIRS model

138 We specified an age-specific ODE (Ordinary Differential Equation) compartmental model to 139 study the dynamics of RSV. The model incorporates epidemiological parameters, including 140 age and sex/gender. We calibrated our model parameters to the measured age-specific titre 141 changes and test different assumptions about the number of susceptible children. We 142 considered the following compartments: immune protected (e.g. maternal or vaccinated), 143 susceptible individuals (subdivided in classes accounting for reinfection potential), infected 144 but not yet infectious (exposed) individuals, infectious, hospitalized, recovered, and dead. 145 The model assumes repeated RSV reinfections increase partial immunity. In contrast to full 146 immunity, partial immunity allows reinfection to occur at a reduced rate. We assumed that 147 susceptible under 15 years have had up to three prior RSV infections. Those above 15 years 148 are assumed to be susceptible individuals with four or more previous RSV infections. Table 1 149 outlines our assumptions of susceptibility levels to reinfection, ranging from 0% to 80% 150 protection against reinfection.

It is made available under a CC-BY-NC-ND 4.0 International license .

151 Table 1: Assumption of estimated immunity level for SEIR (Susceptible-Exposed-Infected-

152 Recovered) Model

Compartment	Immunity	
S ₁ (susceptible)	No protection	
S ₂	25% protection against reinfection in that year	
S ₃	50% protection against reinfection in that year	
S ₄	75% protection against reinfection in that year	
2	80% protection against reinfection in that year	
55	but for persons older 15 years	
P (protection, e.g. vaccinated/maternal/passive	50% protection against reinfection in that year	
immunity)		

153

We estimated the proportion of reinfections per age group in the model using publicly available data from notifications, AGI, and SARI. We formalized the protection compartment only for those 0-1 year old due to maternal/passive immunity as immunisation strategies with vaccines and monoclonal antibodies had not yet been implemented in Germany up to 2023. Figure 2 illustrates the model structure and differential equations (table S1).



It is made available under a CC-BY-NC-ND 4.0 International license .

160 Figure 2: Structure and formula of the models. The compartments are classified either as susceptible (S), 161 exposed (E), infectious (I), hospitalized (H), recovered (R), dead (D), protected (P: vaccination /passive 162 protection), exposed after protection (P_F), infectious after protection (P_I), recovered after protection (P_R). The 163 formula includes the following components: c: Social contact rate; β : The risk of infection; α : The inverse of the 164 incubation period (5 days); p: The proportion of infected individuals requiring hospitalization; y: The inverse of 165 the time an infected individual recovers (7 days); η : The inverse of the time a hospitalized patient recovers (4 166 days); ɛ: The proportion of susceptible individuals gaining full protection; 2: The probability of protected 167 individuals losing full immunity; ϕ : The probability of recovered individuals losing full immunity; σ : The 168 proportion of infected individuals who will die; 0: The proportion of hospitalized patients who will die; 2: The 169 proportion of reinfection in adults (table S1). The detailed equations are provided in the Supplement. 170

We implemented this model with three RSV datasets (figure 3). For each dataset, parameter fitting using an ordinary least squares methodology was two-staged. First, the model was fitted to case data. The parameters obtained here were used as initial guess for the fit to hospitalization data.

175 1. RSV notification model

The model was calibrated with extrapolated notification case data, yielding time-dependent infection parameters and reinfection proportions stratified by age groups. Subsequently, the model was fitted to extrapolated SARI hospital data of RSV specific hospitalizations to derive the corresponding hospitalization parameters from 2016 to 2022.

180 2. RSV population-based model

181 The population-based model was parameterized using pre-pandemic RSV notification data, 182 with results informing assumptions regarding the proportion of susceptible children and the 183 incidence of reinfection in 2021 and 2022. The revised proportion of reinfection for adults 184 was performed according to MuSPAD data for simulation parameters. We calibrated the 185 model using the extrapolated SARI RSV hospitalization data to derive the parameters related 186 to hospitalization.

187 3. RSV notification model incorporating underreporting factor

For the notification model we incorporated the data with an age-specific underreporting
factor. We calculated underreporting ratios by dividing the extrapolated notification
numbers with our estimated case numbers for each age group (Supplement Calculation).

- 191 Using the same methodology for model fitting, we estimated model-based proportions of 192 reinfections across age groups to Germany. We derived the hospitalization parameters by
- 193 fitting the model to the SARI RSV hospitalizations.

It is made available under a CC-BY-NC-ND 4.0 International license .



194

195

196 197

Figure 3: Model simulation process incorporates the integration of three RSV cases datasets and a single hospitalization dataset. The outcomes derived from the model are presented herein (blue).

198 **Results**

We collected from three respectively four study cites 13,861 (Aachen, Magdeburg, Hannover 199 and Greifswald 2021), 3,034 (Aachen, Magdeburg, Hannover 2022) and 2,832 (Aachen, 200 201 Magdeburg, Hannover and Greifswald 2023) blood samples. Among these, there was an 202 overlap of 1,754 individuals with samples from both 2020/21 and 2022, and 836 individuals 203 with samples from 2020/21, 2022, and 2023. The median age was 55 years (IQR 40-67) in 204 2022 (2023: 56 year IQR 41-68) and 60% (2023: 61%) were female (table 2). Among the 205 participants who experienced reinfection in 2021/22, 40% (40/100) have had a previous COVID-19. Subtype analysis using multiplex serology showed that among the 106 206 207 participants reinfected in 2023, of whom 11 (10.4%) were subtype A, 55 (51.9%) subtype B, 208 and 40 (37.7%) were unclear.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 209 Table 2: MuSPAD participant characteristics stratified by RSV reinfection status; sampling in
- season \triangle 2021/2022 and \triangle 2022/2023; Reinfection is defined as a titre increase of 20% in
- 211 post-F-protein and 45% in N-protein between two sampling points (full overview table S1)

	Δ 2020/21-2022		Δ 2022-2023	
	Overall with two sampling points	Reinfected	Overall with three sampling points	Reinfected
Characteristics (total n)	N=1,754	N=100 (5·7%, 95% Cl: 4·7-6·9)	N=836	N=106 (12·7%, 95% CI: 10·5- 15·2)
Sex				
female	1,050 (59·9%)	53 (5·1 %)	511 (61·1%)	62 (12·1%)
male	704 (40·1%)	47 (6·7%)	325 (38.9%)	44 (13·5%)
Age (age in 2022)				
18-29	76 (4·3%)	<6 (3.0%)	23 (2·8%)	9 (39 1%)
30-39	188 (10.7%)	23 (12·2%)	67 (8·0%)	<6 (4.7%)
40-49	202 (11.5%)	15 (7·4%)	87 (10·4%)	9 (10·3%)
50-59	451 (2 <mark>5·7%)</mark>	16 (3·6%)	231 (27.6%)	25(10·8%)
60-69	467 (26·6%)	27 (5·8%)	254 (30·8%)	29 (11·4%)
70-79	278 (15.9%)	13 (4.7%)	140 (16.8%)	23 (16·4%)
80+	92 (5·3%)	<6 (3.0%)	34 (4·1%)	6 (17.6%)
Self-reported current of	comorbidities			
Cancer	27 (1·5%)	<6 (1.0%)	12 (1.5%)	<6 (0.1%)
Cardiovascular disease	123 (7·0%)	<6 (5.0%)	66 (7·9%)	10 (15·2%)
Diabetes Type I & II	86 (5·8%)	<6 (5.0%)	42 (5.0%)	<6 (0.1%)
Hypertension	444 (25·3%)	19 (4·8%)	238 (28·5%)	32 (13·5%)
Immunodeficiency disease	82 (4·7%)	<6 (4.0%)	44 (5·3%)	6 (13·6%)
Chronic lung disease	120 (6·8%)	6 (6·0%)	52 (6·2%)	9 (17·3%)
Household with childre	en under 14	_		
No	1,135 (65.0%)	54 (4·8%)	652 (78·0%)	117 (17·9%)
Yes	247 (14·1%)	22 (8·9%)	71 (8·5%)	14 (19·7%)
SARS-CoV-2 Nucleocar	osid detection(prior	infection)	T	
negative	1,125 (64·1%)	60 (5·3%)	198 (23.7%)	23 (11·6%)
positive	629 (35·9%)	40 (6.4%)	623 (74·5%)	81 (13·0%)
Household (HH) size	1		1	
Median number of HH members (IQR)	2 (2-3)	2 (2-3)	2 (2-3)	2 (2-2)
Household and Non-ho	ousehold contacts			
Median contact number (IQR)	5 (2-9)	6 (3-13)	4 (1-8)	5 (1-10)

It is made available under a CC-BY-NC-ND 4.0 International license .

212

213 RSV Reinfection by age groups

214 We use three adjustment sets accounting for prior SARS-CoV-2 infection (NC), children <14 215 years in household and age. The probability of reinfection is higher for all age groups in 216 season 2022-23 compared to 2021-22 (figure 4). Within season 2022-23, the youngest age 217 group shows the highest probability, followed by the oldest age group (figure 4a). Predicted probabilities for positive and negative SARS-CoV-2 NC antibody responses remain unchanged 218 219 within the age groups (figure 3b). Having children under 14 in the household increases the 220 predicted probability of reinfection for the 2022/23 season (figure 4c). The age group 30-39 221 years exhibited a higher adjusted risk ratio (aRR; Supplement DAG) during 2021-2022 season 222 (aRR: 3.11 95%CI 0.96-10.07) compared to 2022-2023 season (aRR: 0.21 95%CI 0.08-0.56) 223 (figure 4d, table S2).



Figure 4: a) Predicted probability of reinfection over age groups regarding RSV season 2020/21-2022 (red dots) and 2022-2023 (blue dots; upper panel); as b) exposure SARS-CoV-2 prior infection (Nucleocapsid (NC); positive NC=circle and negative NC=square; middle left panel) and c) exposure children under 14 years living in the household (HH) no=triangle and yes=diamante; middle right panel) based on three different models and their adjustment sets. d) Adjusted relative risk (RR=1 (black dashed line; bottom panel) for adjustment set see Supplement DAG)

It is made available under a CC-BY-NC-ND 4.0 International license .

The number of household contacts (figure S2) increased the likelihood of having a
reinfection in 2020/21-2022 (OR 4·22; 95%Cl 0·61-22·20), but not in the 2022/2023 season.
The number of non-household contacts did not have an effect on the odds ratios (OR 0·98;
95%Cl 0·89-1·03).

235 Model-based RSV reinfection proportions

236 We fitted the parameters of our model for RSV using extrapolated data for weekly reports in 237 Germany. With this we estimated the weekly RSV reinfection proportions for pre- and post-238 pandemic seasons by dividing the total infections predicted by our model by the overall 239 population for each season. Model-based reinfection estimates were consistently lower than 240 population-study based reinfection estimates. In pre-pandemic seasons, the pattern and 241 proportion of RSV reinfections in each age group were similar, ranging from 0% to 1.2% 242 (figure 5a). In the 2021/22 season, there was a drop in reinfections, while 2022/23 we saw a 243 sharp increase to 10% in the oldest age group (figure 5b). The mean trends on RSV 244 reinfection consistently mark the importance of the 15-34 age group, leading the dynamics 245 (figure 5c).

246 By comparing the proportion of RSV reinfection from the MuSPAD data and the estimated

247 new notification cases based on SurvStat@RKI, we calculated an underdetection factor for

adult RSV reinfection by adult age group for seasons 2021/22 and 2022/23 (figure 5e), with

high underdetection seen in the 15-34 age group. T (figure 5f).

It is made available under a CC-BY-NC-ND 4.0 International license .



251 Figure 5: Estimated and extrapolated weekly proportion of RSV reinfection by age group based on 252 SurvStat@RKI data over calendar weeks of (a) 2017-2020 and (b) 2021-2023. (c) Estimated proportion of RSV 253 reinfection extrapolated by age group based on SurvStat@RKI data from 2017-2023. (d) Estimated RSV 254 infections by age group based on SurvStat@RKI data and population-based MuSPAD data for the seasons 255 2021/2022 and 2022/2023 by age group and calendar week. Please be aware of the different scales of the y-256 axis. (e) Underdetection factor for RSV reinfection by age group, estimated by comparing the RSV reinfections 257 in MuSPAD with SurvStat@RKI. (f) Underdetection factor of extrapolated reported cases, defined by calculated 258 cases using GrippeWeb and ARI surveillance stratified by age group over the 2018-2023. Unexplained outliers 259 were deleted to ensure validity.

It is made available under a CC-BY-NC-ND 4.0 International license .

260 Projection of RSV cases and hospitalizations

Using SurvStat@RKI data from only Saxony without an underdetection factor, we predicted extrapolated RSV cases for 2023/2024 (figure 6a). We also used population-based data (figure 6b) and SurvStat@RKI data with an estimated underdetection factor (figure 6c) for overall predictions. Although the onset matches previous predictions, predicted cases, except for those 80+, are higher due to the underdetection factor in population-based data.

266 We predicted new RSV hospitalizations using SARI hospitalization data and three sources: 267 SurvStat@RKI without underdetection factor (figure 6d), population-based (MuSPAD (figure 268 6e), and SurvStat@RKI with underdetection factor (figure 6f). The peaks in RSV 269 hospitalizations are predicted from week 45 to 49 for season 2022/23 and 2023/24. The 270 model with population-based data predicts fewer new RSV hospitalizations than 271 SurvStat@RKI data, regardless of the underdetection factor. The inclusion of the 272 underdetection factor in SurvStat@RKI data shows higher hospitalization numbers, 273 especially in the 2-4 years age group, compared to data without it (figure 6d; figure 6f). However, for the 0-1 year age group, the peak in new RSV hospitalizations is slightly lower 274 275 with underdetection than without it.

276 Regarding the prediction of new hospitalizations for the 2023/2024 season, there is a peak 277 delay of about four weeks. Overall the prediction using population-based reinfection 278 estimates is closer in all age-groups to the actual trajectory of cases than the surveillance 279 based predictions. In the 0-1 year age group, the peak predictions in the MuSPAD data 280 (n=4,326) is almost as close as the absolute numbers seen in the SARI RSV hospitalization 281 data (n=3,994). In addition, when compared to the previous two seasons, there was a 282 notable increase in the number of RSV hospitalizations for children aged 2-4 years. The peak 283 predictions in the SurvStat@RKI data with an underdetection factor of 2-4 years of age is 284 nearly the same as the absolute numbers seen in the SARI RSV hospitalization data.

It is made available under a CC-BY-NC-ND 4.0 International license .

286 Figure 6: (a) RSV reported (points), model simulated (solid line) and predicted (dashed line) new cases by age 287 group based on SurvStat@RKI data without underdetection factor and 95%CI (shaded area). (b) RSV model 288 simulated (solid line) and predicted (dashed line) new cases by age group based on MuSPAD data with 95%CI 289 (shaded area). (c) RSV model simulated (solid line) and predicted (dashed line) new cases for 2023/2024 by age 290 group based on SurvStat@RKI with underdetection factor from sentinel data with 95%CI (shaded area). (d) 291 Prediction (points) of new RSV hospitalizations for 2023/2024 by age group based on infected cases 292 SurvStat@RKI data without underdetection. (e) Prediction of new RSV hospitalizations for 2023/2024 by age 293 group based on MuSPAD data. (f) Prediction of new RSV hospitalizations for 2023/2024 by age group based on 294 from SurvStat@RKI data with underdetection factor from sentinel (AGI and GrippeWeb) data.

295

296 Discussion

In this work, we used longitudinal serological population-based MuSPAD data and publicly available sentinel and notification data to parametrize an RSV ODE model to project the RSV dynamics in Germany for the 2023/24 season. We published these projections in a common statement by the modelling network for severe infectious diseases MONID in 2023²⁵, and

It is made available under a CC-BY-NC-ND 4.0 International license .

evaluated there accuracy here, retrospectively. We show a qualitatively adequate forecast with minor deviations from the actual season, in particular using the reinfection estimators provided by serological indicators from the population-based cohort. This lays a necessary foundation for future efforts to model RSV, including with incoming prevention strategies and underscores the necessity of using estimates from population cohorts combined with population-scalable multiplex serological assays.

Our results indicate that the dynamics of RSV reinfections in the adult population are season specific. While in the 2021/22 season reinfections estimates were lower in most age groups apart from the 30-39 year olds than in pre-pandemic periods they were higher in the 2022/23 season²⁶. Young adults (30-39 years) were more likely to be reinfected in 2021/22, and there was a tendency for an association of reinfection risk with having children (<14y) in the household were evident from 2020-2022, but not during 2022-2023.

313 Population-based reinfection estimates for 2021/2022 and 2022/2023 respiratory season 314 help investigate post-pandemic trends, which are not obvious from sentinel and notification data in Germany. Cai et al.²⁷ have described the characteristics of these seasons for children, 315 highlighting how they differ from average pre-pandemic seasons. They show that in both 316 317 seasons hospitalizations for children over two were 3-4 times higher than pre-pandemic 318 levels (1.5-2 times in those <2 years). Our cohort does not include children. However, the 319 higher number of affected older children align with our finding of a higher-than-usual 320 proportion of reinfected adults aged of 30-39 who are likely the parents of these children. 321 This reflects the dynamic effects of an increased infection frequency in the population. In 322 addition to different RSV subtypes being responsible for the seasons (A in 21/22 and B in 323 22/23), this suggests differential infection acquisition in the two seasons. In the 21/22324 season infections were more likely acquired via children in the household whereas in the 325 22/23 season this was more likely via non-household contacts or adult family members. This 326 agrees well with our findings that in the 21/22 season the number of household contacts 327 was associated with reinfection risk.

Comparing reinfection estimates from population-based data with surveillance data we found a mean underdetection factor of 33.8 for RSV infection in the notification data in Germany from 2018 and 2023, although we used a conservative approach to minimise false positive classification, meaning that the reinfection might be even higher. Expectedly, in line with disease severity risk, we found underdetection to be especially high in the 35-59 and 15-34 age groups.

Our ODE model effectively captured dynamic patterns in previous seasons and, when combined with population-based surveillance data, predicted for 2023/2024 a similar

It is made available under a CC-BY-NC-ND 4.0 International license .

pattern as in 2022. Interestingly, the simulation taking into account population-based estimates also yielded results closer to actual dynamics in those age-groups (the children) where no population-based estimates were available. While estimates for this age group would enhance accuracy, this emphasizes the need for estimates of age groups not typically at risk for severe disease²⁸. We integrated protection compartments to our model able to mirror the prevention strategies currently being implemented. To assess these a thorough comprehension of the current RSV dynamics at the population level is necessary.

343 Our study has limitations. First, although we demonstrated the robustness of our results 344 with regard to the thresholds in post-F and N-protein antibodies there is no gold-standard 345 available for this yet. Although a less stringent cut-off has been used in previous studies in specific sub-groups²⁹, our sensitivity analyses showed more reliable results with this more 346 347 conservative approach. The duration between infection and the evaluation of the post-F-348 protein varied among the participants. Here, due to a lack of previous evidence we did not 349 include assumptions for titre waning in our calculations, although this data was included as part of the RSV immunoassay validation²⁴. We also did not include assumptions for the 350 proportion of same-season reinfections and did not investigate those persons (4) with 351 352 serological indication of reinfection in both season further. And while we found no relation 353 between previous SARS-CoV-2 infection and RSV reinfection, we did not assess disease 354 severity, so our findings do not contradict findings of other groups showing a higher risk of 355 notified or clinically apparent RSV infections in those with (recent) SARS-CoV-2 infection.

356 The nationwide mandatory RSV reporting system in Germany from 2023 onwards will have 357 similar detection biases as the previous system in Saxony. Physicians due to the lack of a 358 therapeutic consequence do not normally test patients with mild to moderate ARI or ILI 359 symptoms. Also, not everyone with such symptoms visits a physician, and not all RSV cases 360 show symptoms. Therefore, our approach combining the surveillance system with 361 population-based and additional data sources aids in monitoring the effectiveness of 362 prevention strategies. This would be in particular beneficial in combination with in-depth ARI 363 sentinel systems from day-cares and paediatricians of single federal states, as already in place in some European regions³⁰. With post-pandemic dynamic changes and incoming 364 prevention strategies, appropriate capacities must now be established to provide model-365 366 usable data for accurate projections, build up models able to integrate these data and with 367 that evaluate continuously the effectiveness of prevention strategies so that these may be 368 adapted. We plan to integrate our 2023/24 data projections into MONID and publish them 369 on www.respinow.de as soon as possible.

It is made available under a CC-BY-NC-ND 4.0 International license .

370 Acknowledgements:

371 We sincerely thank all the participants from Aachen, Hannover, Magdeburg and Greifswald 372 for endorsing our study. We are grateful to Kim Busch and Sabine Pape for answering the 373 participant's questions and concerns. We thank our colleagues in Osnabrück laboratories for 374 the laboratory work. We thank Daniela Gornyk and Pilar Hernandez to have built the initial 375 study population (MuSPAD), and Julia Ortmann and Max Hassenstein for the initial data 376 cleaning, and Daniel Alexander Schulze for study assistance and the whole MuSPAD study 377 group (Stefanie Castell, Pilar Hernandez, Monike Schlüter, Gerhard Bojara, Kristin Frank, 378 Knut Grubbe, Torsten Tronn, Oliver Kappert, Winfried Kern, Thomas Illig, Norman Klopp, 379 Gottfried Roller, Michael Ziemons, Daniela Gornyk, Manuela Harries, Stephan Glöckner, 380 Jana-Kristin Heise, Yvonne Kemmling, Barbora Kessel, Gérard Krause, Berit Lange, Henrike 381 Maaß, Julia Ortmann, Monika Strengert, Tobias Kerrines).

382 Funding:

383 The Helmholtz Association, European Union's Horizon 2020 research and innovation 384 program [grant number 101003480], the Federal Ministry of Education and Research (BMBF) 385 as part of the Network University Medicine (NUM) via the egePan Unimed project (grant 386 number: 01KX2021), the IMMUNEBRIDE project (grant number: 01KX2121) and the 387 PREPARED project (grant number: 01KX2121), the Federal Ministry of Education and 388 Research (BMBF) via the RESPINOW (grant number: HZI MV2021-012, NMI FKZ031L0298B) 389 and OptimAgent (grant number: MV2021-014) projects, by the German Research Foundation 390 (DFG) via the SpaceImpact (grant number: KA 5361/7-1), and Epiadaptdiag (grant number: 391 KA 5361/1-1) projects as well as by intramural HZI funds supported this work as well as the 392 initial funding for the MuSPAD Study from the Initiative and Networking Fund of the 393 Helmholtz Association of German Research Centres Grand number SO-96. The NAKO is 394 funded by the Federal Ministry of Education and Research (BMBF) [project funding reference 395 numbers: 01ER1301A/B/C, 01ER1511D, 01ER1801A/B/C/D and 01ER2301A/B/C], federal 396 states of Germany and the Helmholtz Association, the participating universities and the 397 institutes of the Leibniz Association. The NMI receives funding from the Baden-Württemberg 398 Ministry of Economic Affairs, Labor and Tourism (Germany).

399 Data sharing statement:

We will share anonymized data utilized in this study with other academic researchers uponrequest. The variables can include study site information, assay information, bio sample

It is made available under a CC-BY-NC-ND 4.0 International license .

- 402 type, demographic information, and test results. For further information, please contact
- 403 muspad@helmholtz-hzi.de. Additionally, all links to publicly available data sources are in the
- 404 supplement.
- 405 Authors' contributions
- 406 Conceptualization: B.L.
- 407 Data quality: A.M., J.K., M.H., CJ.KT., MA.K., V.J.;
- 408 Formal analyses: A.M., CJ.KT., M.H., I.R., J.K.;
- 409 Visualization: A.M., I.R., CJ.KT., M.H., J.K. S.C;
- 410 Project administration: M.H., B.L., CJ.KT;
- 411 Laboratory analysis: A.D., P.M, N.S.;
- 412 Writing-original draft: M.H., CJ.KT., B.L., I.R. J.K. A.M. S.C.;
- 413 Funding acquisition: B.L., A.K., N.S, St Ca;
- 414 Writing-review & editing: CJ.KT., M.H., I.R., J.K., A.M., V.J., MA.K, B.L., A.K., P.M., A.D., N.S.,
- 415 S.C. St Ca.; JK.H. RESPINOW study group;
- 416 All authors have read and agreed to the published version of the manuscript.

It is made available under a CC-BY-NC-ND 4.0 International license .

418 **References**

Savic M, Penders Y, Shi T, Branche A, Pircon JY. Respiratory syncytial virus disease
burden in adults aged 60 years and older in high-income countries: A systematic literature
review and meta-analysis. *Influenza Other Respir Viruses* 2023; **17**(1): e13031.

422 2. Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections with the 423 respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology and clinical course 424 compared to influenza A / B and the original SARS-CoV-2 strain. *J Clin Virol* 2023; **161**: 425 105399.

Bont L, Versteegh J, Swelsen WT, et al. Natural reinfection with respiratory syncytial
virus does not boost virus-specific T-cell immunity. *Pediatric research* 2002; **52**(3): 363-7.

428 4. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection 429 with respiratory syncytial virus. *Journal of Infectious Diseases* 1991; **163**(4): 693-8.

5. Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, et al. Defining the Burden of Disease
of RSV in the European Union: estimates of RSV-associated hospitalisations in children under
5 years of age. A systematic review and modelling study. *J Infect Dis* 2023.

433 6. Control ECfDPa. Intensified circulation of respiratory syncytial virus (RSV) and 434 associated hospital burden in the EU/EEA. 2023.

435 7. Justiz) BBd. Infektionsschutzgesetz - IfSG §7. 2023.

436 8. Teirlinck AC, Johannesen CK, Broberg EK, et al. New perspectives on respiratory
437 syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic. *Eur*438 *Respir J* 2023; **61**(4).

439 9. Robert-Koch-Institut. RSV notifications for Saxony. 2021 (accessed accessed 09/2021.

440 10. Koltai M, Krauer F, Hodgson D, et al. Determinants of RSV epidemiology following
441 suppression through pandemic contact restrictions. *Epidemics* 2022; **40**: 100614.

Juhn YJ, Wi CI, Takahashi PY, et al. Incidence of Respiratory Syncytial Virus Infection in
Older Adults Before and During the COVID-19 Pandemic. JAMA Netw Open 2023; 6(1):
e2250634.

445 12. Eden JS, Sikazwe C, Xie R, et al. Off-season RSV epidemics in Australia after easing of
446 COVID-19 restrictions. *Nat Commun* 2022; **13**(1): 2884.

Fricke LM, Glöckner S, Dreier M, Lange B. Impact of non-pharmaceutical interventions
targeted at COVID-19 pandemic on influenza burden - a systematic review. *J Infect* 2021;
82(1): 1-35.

45014.EMA. Arexvy. Recombinant respiratory syncytial virus pre-fusion F protein,451adjuvantedwithAS01E.2023.

452 https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy (accessed 05.09.2023.

453 15. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to 454 Prevent RSV Illness in Infants. *N Engl J Med* 2023; **388**(16): 1451-64.

Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C. Early lessons from the
implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting
monoclonal antibodies, Galicia, Spain, September and October 2023. *Eurosurveillance* 2023;
28(49): 2300606.

459 17. ECDC. Vaccine Scheduler: RSV: Recommended vaccinations. 2023. https://vaccine460 schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=53&SelectedCountryIdBy
461 Disease=-1 (accessed 27.05 2024).

462 18. Bundesminsterium Soziales G, Plege und Konsumentenschutz. Impfplan Österreich
463 2023/2024. 2024. https://www.sozialministerium.at/Themen/Gesundheit/Impfen/Impfplan464 %C3%96sterreich.html (accessed 27.05 2024).

465 19. Council SH. Vaccination against RSV (adults). Brussels, 2023.

466 20. Nakajo K, Nishiura H. Age-dependent risk of respiratory syncytial virus infection: A 467 systematic review and hazard modeling from serological data. *J Infect Dis* 2023.

468 21. Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory Syncytial Virus: A
469 Comprehensive Review of Transmission, Pathophysiology, and Manifestation. *Cureus* 2023;
470 15(3): e36342.

471 22. Gornyk D, Harries M, Glockner S, et al. SARS-CoV-2 Seroprevalence in Germany. *Dtsch* 472 *Arztebl Int* 2021; **118**(48): 824-31.

473 23. Harries M, Jaeger VK, Rodiah I, et al. Bridging the gap-estimation of 2022/2023 SARS474 CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic
475 panel. *International Journal of Infectious Diseases* 2024; **139**: 50-8.

476 24. Marsall P, Fandrich M, Griesbaum J, et al. Development and validation of a 477 respiratory syncytial virus multiplex immunoassay. *Infection* 2024; **5**2(2): 597-609.

25. Calero Valdez AC, Tim; Greiner, Wolfgang; Karch, André; Kheifetz, Yuri; Kirsten,
Holger; Kretzschmar, Mirjam; Kühn, Martin; Kuhlmann, Alexander; Lange, Berit; Leithäuser,
Neele; Mikolajczyk, Rafael; Mohring, Jan; Nagel, Kai; Priesemann, Viola; Rehmann, Jakob;
Rodiah, Isti; Scholz, Markus; Schütte, Christof; Steinmann, Maren. Szenarien zur Belastung
der Bevölkerung und des Gesundheitswesens durch SARS-CoV-2-Infektionen im Winter
2023/24 und Einschätzungen zur Belastung durch andere Atemwegsinfektionen. Zenodo
2023.

485 26. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus 486 activity in Europe during the 2020/21 season: what can we expect in the coming summer 487 and autumn/winter? *Eurosurveillance* 2021; **26**(29): 2100639.

27. Cai W, Köndgen S, Tolksdorf K, et al. Atypical age distribution and high disease
severity in children with RSV infections during two irregular epidemic seasons throughout
the COVID-19 pandemic, Germany, 2021 to 2023. *Eurosurveillance* 2024; **29**(13): 2300465.

28. Rodiah I, Vanella P, Kuhlmann A, et al. Age-specific contribution of contacts to
transmission of SARS-CoV-2 in Germany. *European Journal of Epidemiology* 2023; **38**(1): 3958.

494 29. Capella C, Chaiwatpongsakorn S, Gorrell E, et al. Prefusion F, postfusion F, G 495 antibodies, and disease severity in infants and young children with acute respiratory 496 syncytial virus infection. *The Journal of infectious diseases* 2017; **216**(11): 1398-406.

497 30. NLGA. [Respiratory diseases /Influenza] Atemwegserkrankungen / Influenza. 2023.
498 https://www.nlga.niedersachsen.de/are/uebersicht-205132.html.